Show simple item record

dc.creatorChopera, Denis R.
dc.creatorMann, Jaclyn K.
dc.creatorMwimanzi, Philip.
dc.creatorOmarjee, Saleha.
dc.creatorKuang, Xiaomei T.
dc.creatorNdabambi, Nonkululeko.
dc.creatorGoodier, Sarah.
dc.creatorMartin, Eric.
dc.creatorNaranbhai, Vivek.
dc.creatorAbdool Karim, Salim Safurdeen.
dc.creatorAbdool Karim, Quarraisha.
dc.creatorBrumme, Zabrina L.
dc.creatorNdung’u, Thumbi.
dc.creatorWilliamson, Carolyn.
dc.creatorBrockman, Mark A.
dc.date.accessioned2016-10-24T07:19:07Z
dc.date.available2016-10-24T07:19:07Z
dc.date.created2013
dc.date.issued2013
dc.identifier.citationChopera, D.R., Mann, J.K., Mwimanzi, P., Omarjee, S., Kuang, X.T., Ndabambi, N., Goodier, S., Martin, E., Naranbhai, V., Karim, S.A. and Karim, Q.A. 2013. No evidence for selection of HIV-1 with enhanced Gag-Protease or Nef function among breakthrough infections in the CAPRISA 004 tenofovir microbicide trial. PloS one 8(8), e71758.en_US
dc.identifier.urihttp://dx.doi.org/10.1371/journal.pone.0071758.en_US
dc.identifier.urihttp://hdl.handle.net/10413/13535
dc.descriptionCAPRISA, 2013.en_US
dc.description.abstractBackground: Use of antiretroviral-based microbicides for HIV-1 prophylaxis could introduce a transmission barrier that inadvertently facilitates the selection of fitter viral variants among incident infections. To investigate this, we assessed the in vitro function of gag-protease and nef sequences from participants who acquired HIV-1 during the CAPRISA 004 1% tenofovir microbicide gel trial. Methods and Results: We isolated the earliest available gag-protease and nef gene sequences from 83 individuals and examined their in vitro function using recombinant viral replication capacity assays and surface protein down regulation assays, respectively. No major phylogenetic clustering and no significant differences in gag-protease or nef function were observed in participants who received tenofovir gel versus placebo gel prophylaxis. Conclusion: Results indicate that the partial protective effects of 1% tenofovir gel use in the CAPRISA 004 trial were not offset by selection of transmitted/early HIV-1 variants with enhanced Gag-Protease or Nef fitness.en_US
dc.language.isoenen_US
dc.titleNo evidence for selection of HIV-1 with enhanced gag-protease or nef function among breakthrough infections in the CAPRISA 004 tenofovir microbicide trial.en_US
dc.typePeer reviewed journal articleen_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record